<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862952</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2013/211</org_study_id>
    <nct_id>NCT01862952</nct_id>
  </id_info>
  <brief_title>Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy</brief_title>
  <acronym>Video-EEG</acronym>
  <official_title>Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is a major cause of epilepsy. The pathophysiological mechanisms of poststroke
      epilepsy are not known. Subclinical epileptiform discharges could contribute to the neuronal
      damage and influence functional outcome. Electro-encefalography (EEG) is the golden standard
      to detect interictal, ictal and subclinical epileptic brain activity.

      Patients admitted to the stroke unit with an ischemic or hemorrhagic cerebrovascular attack
      will undergo a 24 hours video-EEG monitoring to detect epileptiform discharges. Clinical and
      paraclinical (imaging, serum markers of neuronal damage) parameters will be analysed
      together with the EEG results. The EEG results will be correlated with the occurence of
      epileptic seizures and functional outcome and mortality in the acute phase and in the
      long-term. When subclinical epileptic discharges are found on the EEG, patients will be
      asked to participate in a second part of the study where they will be randomised into a
      treatment (with an anti-epileptic drug) versus no-treatment group for a period of 6 months.
      Outcome parameters will be the occurrence of epileptic seizures, mortality and functional
      outcome.

      Our main hypothesis is that the occurrence of subclinical epileptiform discharges during the
      acute phase following stroke influences functional outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified ranking scale and NIHSS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>at month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified ranking scale and NIHSS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>medical records, seizure diary, interrogation of patient and caregiver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of epileptic seizures</measure>
    <time_frame>at month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>medical records, seizure diary, interrogation of patient and caregiver</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>antiepileptic treatment as used in daily clinical practice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiepileptic treatment as used in daily clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>starting of anti-epileptic drug treatment</intervention_name>
    <arm_group_label>antiepileptic treatment as used in daily clinical practice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ischemic arteria cerebri media infarct and spontaneous intraparenchymal
             bleeding

        Exclusion Criteria:

          -  Patients with subarachnoidal haemorrhage, traumatic haemorrhage (epidural/subdural
             bleeding), cerebral venous sinus thrombosis, epilepsy, anti-epileptic treatment,
             transient ischemic attack, indication for urgent neurosurgical intervention
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veerle De Herdt, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veerle De Herdt, MD, Phd</last_name>
    <email>Veerle.deherdt@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle De Herdt, MD, Phd</last_name>
    </contact>
    <contact_backup>
      <last_name>Dimitri Hemelsoet, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Veerle De Herdt, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 4, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
